Market Research Reports and Industry Reports

Rising Stars Outlook 2016 :New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH)

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there is a worldwide need for new therapies to treat the global epidemic of NASH and the cost to society will be huge if it is not addressed in the upcoming years! Besides, scarcity of treatment options, there is also an urgent unmet need to develop biomarkers that facilitate the diagnosis, identification of populations at risk, assessment of disease progression or regression, and/or response to treatment. The potential market is gigantic with analysts predicting north of $35bn by 2025!

Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, we expect many Giants to join this race and thus, we can see more Licensing deals/ M&A activity on the horizon! In light of recent developments in NASH, we have added few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year.
Figure 1
Conatus Pharma
EMRICASAN: DATA FROM PHII, LIVER CIRRHOSIS TRIAL (3-MONTHS)

Figure 2
Conatus Pharma
EMRICASAN: MEDICAL NEED AND MARKET OPPORTUNITIES
Figure 3
Conatus Pharma
EMRICASAN: A POTENT INHIBITOR OF APOPTOTIC AND INFLAMMATORY CASPASES
Figure 4
Conatus Pharma
EMRICASAN: PHASE II, LIVER CIRRHOSIS TRIAL (3 MONTHS)
Figure 5
Conatus Pharma
EMRICASAN: PHASE II DATA @ EASL, 2015
Figure 6
Conatus Pharma
EMRICASAN: PHASE II DATA @ AASLD, 2015
Figure 1
Galectin Therapeutics
ROLE OF GALECTIN-3 IN PATHOPHYSIOLOGY OF NASH AND FIBROGENESIS
Figure 2
Galectin Therapeutics
PHASE II TRIAL DESIGNS: NASH-CX (W/ CIRRHOSIS) & NASH-FX (W/ ADVANCED FIBROSIS
Figure 3
Galectin Therapeutics
GR-MD-02: PHI STUDY SERUM BIOMARKERS EVALUATION
Figure 4
Galectin Therapeutics
GR-MD-02: PRECLINICAL DATA TX EFFECT ON NASH WITH FIBROSIS
Figure
Galectin Therapeutics
PIPELINE PORTFOLIO
Figure 1
Galmed Pharmaceuticals
ARAMCHOL: PHASE IIA DATA RELATIVE CHANGE IN LIVER-FAT CONCENTRATION
Figure 2
Galmed Pharmaceuticals
ARAMCHOL: DIFFERENTIATED MODE OF ACTION
Figure 3
Galmed Pharmaceuticals
ARAMCHOL: CLINICAL TRIALS AND ITS ENDPOINTS
Figure 4
Galmed Pharmaceuticals
PHIIA RESULTS: CHANGES IN CHOLESTEROL AND SERUM ADIPONECTIN LEVELS
Figure 5
Galmed Pharmaceuticals
CHANGES IN THE LEVELS OF CHOLESTEROL CRYSTALLIZATION AFTER THE ADDITION OF ARAMCHOL
Figure 1
Genfit SA
GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
Figure 2
Genfit SA
GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
Figure 3
Genfit SA
ELAFIBRANOR: PPAR REGULATES NUMEROUS PATHWAYS ESSENTIAL IN NASH
Figure 4
Genfit SA
ELAFIBRANOR: PHASE III TRIAL DESIGN

Figure 5A
Genfit SA
GOLDEN-505: IMPROVEMENT IN CARDIO-METABOLIC AND GLYCEMIC PARAMETERS
Figure 6
Genfit SA
EFFICACY OF GFT505 IN ANIMAL MODELS OF NAFLD/ NASH AND LIVER FIBROSIS
Figure 7
Genfit SA
EFFICACY OF GFT505 IN ANIMAL MODELS OF NAFLD/ NASH AND LIVER FIBROSIS
Figure 8
Genfit SA
EFFECTS OF GFT505 IN RATS WITH ESTABLISHED HEPATIC FIBROSIS
Figure 1
Intercept Pharmaceuticals
GLOBAL PBC PATIENT WATERFALL
Figure 2
Intercept Pharmaceuticals
FLINT STUDY RESULTS: IMPROVEMENT IN NAS, FIBROSIS, AND NASH RESOLUTION
Figure 3
Intercept Pharmaceuticals
FXR IS CENTRAL TO A MULTITUDE OF PATHWAYS
Figure 4
Intercept Pharmaceuticals
POOLED DATA IN PBC: ABSOLUTE AND PERCENT REDUCTION IN ALP
Figure 5
Intercept Pharmaceuticals
POISE STUDY: MET THE PRIMARY ENDPOINT AS EARLY AS 2 WEEKS
Figure 6
Intercept Pharmaceuticals
FLINT STUDY: RESPONSE RATES, FIBROSIS IMPROVEMENT, AND PROGRESSION IN HIGH-RISK PATIENT GROUPS
Figure 7
Intercept Pharmaceuticals
FLINT STUDY: RESPONSE RATES, FIBROSIS IMPROVEMENT, AND PROGRESSION IN HIGH-RISK PATIENT GROUPS
Figure 8
Intercept Pharmaceuticals
HEALTH ECONOMICS MODELLING FOR PBC AND LIVER DISEASE
Figure 9
Intercept Pharmaceuticals
PIPELINE PORTFOLIO
Figure 1
Tobira Therapeutics
CENTAUR - PHIIB CLINICAL TRIAL VS. OTHER PUBLISHED PHIIB STUDIES IN NASH
Figure 2
Tobira Therapeutics
CENICRIVIROC (CVC): A POTENT INHIBITOR OF INFILTRATION OF PRO-INFLAMMATORY MONOCYTES
Figure 3
Tobira Therapeutics
CENICRIVIROC (CVC): NASH MOUSE MODEL REDUCTION IN FIBROSIS AND NAFLD ACTIVITY SCORE (NAS)
Figure 4
Tobira Therapeutics
CENICRIVIROC (CVC): LIPID PROFILE CHANGES FROM BASELINE
Figure 5
Tobira Therapeutics
CENICRIVIROC (CVC): LIPID PROFILE CHANGES FROM BASELINE
Figure 6
Tobira Therapeutics
CENICRIVIROC (CVC): PRODUCT PIPELINE
Chart 1:
Daiichi Sankyo
Efficacy comparison of Quizartinib vs. ASP-2215
Chart 4
Daiichi Sankyo
New NOAC share vs. Warfarin- Warfarin still holds >60% share in US

New NOAC share vs. Warfarin- Warfarin still holds >60% share in US
iichi Sankyo
US TRX of each NOAC since launch



List Of Tables

KEY MILESTONES (CNAT)
Gelectin Therapeutics : Key Milestone Table
Table1
Conatus Pharma
PHIIB, ENCORE PROGRAM IN DIFFERENT ETIOLOGIES & STAGES
Table 2
Conatus Pharma
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH

Table 1
Galectin Therapeutics
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH

Galmed - Key Milestone Table
Table 1
Galmed Pharmaceuticals
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH

Table 1
Genfit SA
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH
Intercept : Key Milestone Table
Table 1
Intercept Pharmaceuticals
COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH

Table 1
Tobira Therapeutics
DRUGS IN DEVELOPMENT FOR NASH
Table 2
Tobira Therapeutics
CENICRIVIROC (CVC): PHIIB DATA IN HIV PTS FAVORABLE 48-WEEK SAFETY (COMBINED WITH FTC/TDF)

List Of Figures

Figure 1
Conatus Pharma
EMRICASAN: DATA FROM PHII, LIVER CIRRHOSIS TRIAL (3-MONTHS)

Figure 2
Conatus Pharma
EMRICASAN: MEDICAL NEED AND MARKET OPPORTUNITIES
Figure 3
Conatus Pharma
EMRICASAN: A POTENT INHIBITOR OF APOPTOTIC AND INFLAMMATORY CASPASES
Figure 4
Conatus Pharma
EMRICASAN: PHASE II, LIVER CIRRHOSIS TRIAL (3 MONTHS)
Figure 5
Conatus Pharma
EMRICASAN: PHASE II DATA @ EASL, 2015
Figure 6
Conatus Pharma
EMRICASAN: PHASE II DATA @ AASLD, 2015
Figure 1
Galectin Therapeutics
ROLE OF GALECTIN-3 IN PATHOPHYSIOLOGY OF NASH AND FIBROGENESIS
Figure 2
Galectin Therapeutics
PHASE II TRIAL DESIGNS: NASH-CX (W/ CIRRHOSIS) & NASH-FX (W/ ADVANCED FIBROSIS
Figure 3
Galectin Therapeutics
GR-MD-02: PHI STUDY SERUM BIOMARKERS EVALUATION
Figure 4
Galectin Therapeutics
GR-MD-02: PRECLINICAL DATA TX EFFECT ON NASH WITH FIBROSIS
Figure
Galectin Therapeutics
PIPELINE PORTFOLIO
Figure 1
Galmed Pharmaceuticals
ARAMCHOL: PHASE IIA DATA RELATIVE CHANGE IN LIVER-FAT CONCENTRATION
Figure 2
Galmed Pharmaceuticals
ARAMCHOL: DIFFERENTIATED MODE OF ACTION
Figure 3
Galmed Pharmaceuticals
ARAMCHOL: CLINICAL TRIALS AND ITS ENDPOINTS
Figure 4
Galmed Pharmaceuticals
PHIIA RESULTS: CHANGES IN CHOLESTEROL AND SERUM ADIPONECTIN LEVELS
Figure 5
Galmed Pharmaceuticals
CHANGES IN THE LEVELS OF CHOLESTEROL CRYSTALLIZATION AFTER THE ADDITION OF ARAMCHOL
Figure 1
Genfit SA
GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
Figure 2
Genfit SA
GOLDEN-505: COMPARISON WITH OTHER PHII STUDIES
Figure 3
Genfit SA
ELAFIBRANOR: PPAR REGULATES NUMEROUS PATHWAYS ESSENTIAL IN NASH
Figure 4
Genfit SA
ELAFIBRANOR: PHASE III TRIAL DESIGN

Figure 5A
Genfit SA
GOLDEN-505: IMPROVEMENT IN CARDIO-METABOLIC AND GLYCEMIC PARAMETERS
Figure 6
Genfit SA
EFFICACY OF GFT505 IN ANIMAL MODELS OF NAFLD/ NASH AND LIVER FIBROSIS
Figure 7
Genfit SA
EFFICACY OF GFT505 IN ANIMAL MODELS OF NAFLD/ NASH AND LIVER FIBROSIS
Figure 8
Genfit SA
EFFECTS OF GFT505 IN RATS WITH ESTABLISHED HEPATIC FIBROSIS
Figure 1
Intercept Pharmaceuticals
GLOBAL PBC PATIENT WATERFALL
Figure 2
Intercept Pharmaceuticals
FLINT STUDY RESULTS: IMPROVEMENT IN NAS, FIBROSIS, AND NASH RESOLUTION
Figure 3
Intercept Pharmaceuticals
FXR IS CENTRAL TO A MULTITUDE OF PATHWAYS
Figure 4
Intercept Pharmaceuticals
POOLED DATA IN PBC: ABSOLUTE AND PERCENT REDUCTION IN ALP
Figure 5
Intercept Pharmaceuticals
POISE STUDY: MET THE PRIMARY ENDPOINT AS EARLY AS 2 WEEKS
Figure 6
Intercept Pharmaceuticals
FLINT STUDY: RESPONSE RATES, FIBROSIS IMPROVEMENT, AND PROGRESSION IN HIGH-RISK PATIENT GROUPS
Figure 7
Intercept Pharmaceuticals
FLINT STUDY: RESPONSE RATES, FIBROSIS IMPROVEMENT, AND PROGRESSION IN HIGH-RISK PATIENT GROUPS
Figure 8
Intercept Pharmaceuticals
HEALTH ECONOMICS MODELLING FOR PBC AND LIVER DISEASE
Figure 9
Intercept Pharmaceuticals
PIPELINE PORTFOLIO
Figure 1
Tobira Therapeutics
CENTAUR - PHIIB CLINICAL TRIAL VS. OTHER PUBLISHED PHIIB STUDIES IN NASH
Figure 2
Tobira Therapeutics
CENICRIVIROC (CVC): A POTENT INHIBITOR OF INFILTRATION OF PRO-INFLAMMATORY MONOCYTES
Figure 3
Tobira Therapeutics
CENICRIVIROC (CVC): NASH MOUSE MODEL REDUCTION IN FIBROSIS AND NAFLD ACTIVITY SCORE (NAS)
Figure 4
Tobira Therapeutics
CENICRIVIROC (CVC): LIPID PROFILE CHANGES FROM BASELINE
Figure 5
Tobira Therapeutics
CENICRIVIROC (CVC): LIPID PROFILE CHANGES FROM BASELINE
Figure 6
Tobira Therapeutics
CENICRIVIROC (CVC): PRODUCT PIPELINE
Chart 1:
Daiichi Sankyo
Efficacy comparison of Quizartinib vs. ASP-2215
Chart 4
Daiichi Sankyo
New NOAC share vs. Warfarin- Warfarin still holds >60% share in US

New NOAC share vs. Warfarin- Warfarin still holds >60% share in US
iichi Sankyo
US TRX of each NOAC since launch



Global Minerals Comprising Beryllium Market Research Report 2016

Notes:Production, means the output of Minerals Comprising BerylliumRevenue, means the sales value of Minerals Comprising BerylliumThis report studies Minerals Comprising Beryllium in Global market, especially in North America, Europe, China,

USD 2900View Report

Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies

Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies        Osteoporosis, the most common metabolic bone

USD 4995View Report

Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars

Innovative and improved drugs therapies developed through novel target discovery and technology platforms have originated from the backyards of small research focused companies (Rising Stars, RS, non-profitable biotech companies). The

USD 2500View Report

Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars

Innovative and improved drugs therapies developed through novel target discovery and technology platforms have originated from the backyards of small research focused companies (Rising Stars, RS, non-profitable biotech companies). The

USD 2500View Report

Global Rising Stars Outlook 2015: Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets.

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets , approaches and biology is discovered. One field which is poised to bring a paradigm

USD 2000View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 2000
  • Site Licence    $ 4000
  • Enterprisewide Licence    $ 6000
$ 2000

Reports Details

Published Date : Jan 2016
No. of Pages :56
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment